Tepotinib Efficacy and Safety in MET Exon 14 Skipping NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Clin. Cancer Res 2021 Nov 17;[EPub Ahead of Print], X Le, H Sakai, E Felip, R Veillon, MC Garassino, J Raskin, AB Cortot, S Viteri, J Mazieres, EF Smit, M Thomas, WT Iams, BC Cho, HR Kim, JC Yang, YM Chen, JD Patel, CM Bestvina, K Park, F Griesinger, M Johnson, M Gottfried, C Britschgi, J Heymach, E Sikoglu, K Berghoff, KM Schumacher, R Bruns, G Otto, PK PaikFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.